ProCE Banner Activity

Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

Podcast Episodes
In this podcast episode, listen to Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, as they answer questions on managing NF1 and using MEK inhibitors for NF1-associated plexiform neurofibromas.

Released: July 12, 2021

Expiration: July 11, 2022

No longer available for credit.

Share

Faculty

Scott Plotkin

Scott Plotkin, MD, PhD

Professor of Neurology
Division of Neuro-Oncology
Harvard Medical School
Neurologist
Department of Neurology
Massachusetts General Hospital
Boston, Massachusetts

Brian D. Weiss

Brian D. Weiss, MD

Clinical Professor of Pediatrics
Division of Oncology
Cancer and Blood Diseases Institute
Cincinnati Childrens Hospital Medical Center
Medical Director, Solid Tumor Program
Division of Oncology
Cincinnati Childrens Hospital
Cincinnati, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Scott Plotkin, MD, PhD

Professor of Neurology
Division of Neuro-Oncology
Harvard Medical School
Neurologist
Department of Neurology
Massachusetts General Hospital
Boston, Massachusetts

Brian D. Weiss, MD

Clinical Professor of Pediatrics
Division of Oncology
Cancer and Blood Diseases Institute
Cincinnati Childrens Hospital Medical Center
Medical Director, Solid Tumor Program
Division of Oncology
Cincinnati Childrens Hospital
Cincinnati, Ohio